BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® for Children With Achondroplasia
BioMarin Announces New Three-Year VOXZOGO® Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® in Children with Hypochondroplasia
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® for Adolescents 12 Years of Age and Older with Phenylketonuria
BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
Summit Royalties Secures Up to US$50 Million Revolving Credit Facility; Provides Other Corporate Updates
NextSource Materials Announces Updated Feasibility Study Results for Molo Mine Expansion to 150k tpa of SuperFlake Graphite Concentrate
